Reslizumab

็‘žๆ–ฏๅˆฉ็ ๅ•ๆŠ—

Report date: 2024/06/21 14:01:01

Base Information

Drug NameReslizumab
Drug Alias NameAnti-interleukin-5 monoclonal antibody็‘žๅˆฉ็ ๅ•ๅ…‹้š†ๆŠ—ไฝ“Reslizumabum็‘žๅˆฉ็ ๅ•ๆŠ—Cinquil +[13]ย 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-5 inhibitors
TargetsInterleukin-5
Therapy Area/IndicationsHypereosinophilic SyndromePulmonary EosinophiliaAsthma +[6]ย 
Global Approved IndicationsAsthma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/03/23
Country/TerritoryCzechiaBelgiumCanada +[36]ย 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active IndicationsAsthma
Inactive IndicationsHypereosinophilic SyndromePulmonary EosinophiliaEosinophilic Esophagitis +[5]ย 

Other Information

ATC CodeR03DX08
Related LinksWikipediaKEGG